DrugBiological
Lebrikizumab clinical trials
Also written LY3650150, DRM06 and Ebglyss.
Keep track of what changes. Save the lebrikizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
46 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 11
Who runs them
Industry 42 · Other 4
Eli Lilly and Company (17) · Hoffmann-La Roche (11) · Genentech, Inc. (7) · Almirall, S.A. (6) · Johann E Gudjonsson MD PhD (1) · Forefront Dermatology S.C (1) · University of Maryland, Baltimore (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Pirfenidone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)
Studies
Open first, then newest update. How each study uses lebrikizumab is read from its arms, and is right about nine times in ten.
Testing it · 46
- A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic DermatitisNot yet recruitingPhase 3Almirall, S.A.NCT07873801Written as Lebrikizumab
- AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered OutcomesNot yet recruitingPhase 4Forefront Dermatology S.CNCT07856134Written as Lebrikizumab-lbkz
- Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis PatientsNot yet recruitingPhase 2University of Maryland, BaltimoreNCT07620561Written as Lebrikizumab
- A Study of Lebrikizumab in Adults With Nummular EczemaRecruitingPhase 3Almirall, S.A.NCT07542483Written as Lebrikizumab
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisEnrolling by invitationPhase 3Eli Lilly and CompanyNCT05735483Written as Lebrikizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Lebrikizumab
- A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Eli Lilly and CompanyNCT06280716Written as Lebrikizumab
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch BurdenCompletedPhase 4Eli Lilly and CompanyNCT07006792Written as Lebrikizumab
- Lebrikizumab in Moderate-to-severe Atopic DermatitisActive, not recruitingPhase 4Johann E Gudjonsson MD PhDNCT06906497Written as lebrikizumab
- A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Hoffmann-La RocheNCT02546700Written as Lebrikizumab
- A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisCompletedPhase 3Eli Lilly and CompanyNCT06921759Written as Lebrikizumab
- A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 3Eli Lilly and CompanyNCT05559359Written as Lebrikizumab
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaCompletedPhase 3Hoffmann-La RocheNCT02104674Written as Lebrikizumab
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationCompletedPhase 3Hoffmann-La RocheNCT01867125Written as Lebrikizumab
- Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Almirall, S.A.NCT05990725Written as Lebrikizumab
- A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationTerminatedPhase 3Hoffmann-La RocheNCT01875003Written as Lebrikizumab
- Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic DermatitisCompletedPhase 3Almirall, S.A.NCT05916365Written as Lebrikizumab
- A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisActive, not recruitingPhase 3Almirall, S.A.NCT06526182Written as Lebrikizumab
- A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of ColorCompletedPhase 3Eli Lilly and CompanyNCT05372419Written as Lebrikizumab
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With DupilumabCompletedPhase 3Eli Lilly and CompanyNCT05369403Written as Lebrikizumab
See all 46 studies that test lebrikizumab →
As the comparator · 1 — what is tested is compared with lebrikizumab
Codes
What other systems call lebrikizumab · ClinicalTrials.gg INT005906
- MeSH (NLM) C561806lebrikizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U9JLP7V031LEBRIKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3829321lebrikizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87767LebrikizumabOne source FDA
- DrugBank DB11914One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561806 | lebrikizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U9JLP7V031 | LEBRIKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3829321 | lebrikizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87767 | Lebrikizumab | One source FDA |
| DrugBank | DB11914 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.